Profile data is unavailable for this security.
About the company
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.
- Revenue in USD (TTM)6.15bn
- Net income in USD1.47bn
- LocationZoetis Inc10 Sylvan WayPARSIPPANY 07054-3825United StatesUSA
- Phone+1 (973) 822-7000
- Fax+1 (302) 655-5049
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|ZTS:NYQ since |
|ZNLabs LLC||Deal completed||22 Nov 2019||22 Nov 2019Deal completed||16.59%||--|
|Phoenix Central Laboratory For Veterinarians Inc||Deal completed||31 Oct 2019||31 Oct 2019Deal completed||9.84%||--|
|Platinum Performance Inc||Deal completed||22 Jul 2019||22 Jul 2019Deal completed||22.85%||--|